Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.64 |
| ▸ | PPARD | Q03181 | 7/20 | 0.62 |
| ▸ | PPARG | P37231 | 7/20 | 0.62 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.60 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.60 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.60 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.60 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.60 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118153 | 0.90 | PPARA (0.53) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL5974323 | 0.88 | PPARA (0.72) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL13460899 | 0.85 | PSEN1 (0.62) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL3415075 | 0.83 | PPARD (0.79) | PPARAPPARDPPARG | |
| SCHEMBL2089153 | 0.80 | PPARA (0.69) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL5974097 | 0.80 | PPARA (0.80) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL5974498 | 0.79 | PPARA (0.72) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL6380273 | 0.78 | PPARA (0.84) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL6497829 | 0.78 | PPARA (1.00) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL4663813 | 0.78 | HPGD (0.72) | PPARAPPARDPPARGPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1844003-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006080884-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | P2RX2, P2RX1, ADORA1 | PPARA 1339/4885PPARD 779/4885PPARG 800/4885 |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | PPARA 130/4885PPARD 689/4885PPARG 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.